> Details

Mondorf, Yvonne; Mikuteit, Marie; Ivanyi, Philipp; Stöhr, Christine; Herrmann, Edwin; Polifka, Iris; Agaimy, Abbas; Trojan, Lutz; Ströbel, Philipp; Becker, Frank; Wülfing, Christian; Barth, Peter; Stöckle, Michael; Staehler, Michael; Stief, Christian G.; Haferkamp, Axel; Hohenfellner, Markus; Macher-Göppinger, Stephan; Wullich, Bernd; Noldus, Joachim; Brenner, Walburgis; Roos, Frederik C.; Walter, Bernhard; Otto, Wolfgang; [...]

The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma
  • Contributor: Mondorf, Yvonne; Mikuteit, Marie; Ivanyi, Philipp; Stöhr, Christine; Herrmann, Edwin; Polifka, Iris; Agaimy, Abbas; Trojan, Lutz; Ströbel, Philipp; Becker, Frank; Wülfing, Christian; Barth, Peter; Stöckle, Michael; Staehler, Michael; Stief, Christian G.; Haferkamp, Axel; Hohenfellner, Markus; Macher-Göppinger, Stephan; Wullich, Bernd; Noldus, Joachim; Brenner, Walburgis; Roos, Frederik C.; Walter, Bernhard; Otto, Wolfgang; [...]
  • imprint: S. Karger AG, 2022
  • Published in: Urologia Internationalis
  • Language: English
  • DOI: 10.1159/000525016
  • ISSN: 1423-0399; 0042-1138
  • Keywords: Urology
  • Origination:
  • Footnote:
  • Description: <jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor and PD-L1 are important prognostic markers. In contrast, the role of programmed death-2 ligand (PD-L2) as prognostic marker remains unclear. The aim of this study was to evaluate if PD-L2 expression could play a role as a prognostic marker for papillary RCC (pRCC). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from &lt;i&gt;n&lt;/i&gt; = 240 and &lt;i&gt;n&lt;/i&gt; = 128 patients with type 1 and 2 pRCC, respectively. Expression of PD-L2 was determined by immunohistochemistry. In total, PD-L2 staining was evaluable in 185 of 240 type 1 and 99 of 128 type 2 pRCC cases. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; PD-L2 staining was positive in 67 (36.2%) of type 1 and in 31 (31.3%) of type 2 pRCC specimens. The prevalence of PD-L2+ cells was significantly higher in high-grade type 1 tumors (&lt;i&gt;p&lt;/i&gt; = 0.019) and in type 2 patients with metastasis (&lt;i&gt;p&lt;/i&gt; = 0.002). Kaplan-Meier analysis disclosed significant differences in 5-year overall survival (OS) for patients with PD-L2− compared to PD-L2+ in pRCC type 1 of 88.4% compared to 73.6% (&lt;i&gt;p&lt;/i&gt; = 0.039) and type 2 of 78.8% compared to 39.1% % (&lt;i&gt;p&lt;/i&gt; &amp;#x3c; 0.001). However, multivariate analysis did not identify the presence of PD-L2+ cells neither in type 1 nor type 2 pRCC as an independent predictor of poor OS. &lt;b&gt;&lt;i&gt;Discussion/Conclusion:&lt;/i&gt;&lt;/b&gt; PD-L2 expression did not qualify as an independent prognostic marker in pRCC. Future studies will have to determine whether anti-PD-L2-targeted treatment may play a role in pRCC and expression can potentially serve as a predictive marker for these therapeutic approaches. </jats:p>